

2020 Regular Session

HOUSE BILL NO. 291

BY REPRESENTATIVE DAVIS

CHILDREN/NEWBORNS: Adds mucopolysaccharidosis type I and glycogen storage disorder type II to the state's newborn screening panel

1 AN ACT

2 To amend and reenact R.S. 40:1081.2(A)(1), relative to the state's newborn screening panel;  
3 to add mucopolysaccharidosis type I and glycogen storage disorder type II to the  
4 panel; to provide an effective date; and to provide for related matters.

5 Be it enacted by the Legislature of Louisiana:

6 Section 1. R.S. 40:1081.2(A)(1) is hereby amended and reenacted to read as follows:

7 §1081.2. Tests

8 A.(1) The physician attending a newborn child, or the person attending a  
9 newborn child who was not attended by a physician, shall cause the child to be  
10 subjected to tests for phenylketonuria, congenital hypothyroidism, sickle cell  
11 diseases, biotinidase deficiency, congenital adrenal hyperplasia, carnitine uptake  
12 defect, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, medium-chain  
13 acyl-CoA dehydrogenase deficiency, trifunctional protein deficiency, very long-  
14 chain acyl-CoA dehydrogenase deficiency, glutaric acidemia type I, 3-hydroxy-3-  
15 methylglutaryl-CoA lyase deficiency, isovaleric acidemia, 3-methylcrotonyl-CoA  
16 carboxylase deficiency, methylmalonic acidemia (CBL A,B), beta ketothiolase,  
17 methylmalonic acidemia (MUT), propionic acidemia, multiple carboxylase  
18 deficiency, argininosuccinate acidemia, citrullinemia type I, homocystinuria, maple  
19 syrup urine disease, tyrosinemia type I, mucopolysaccharidosis type I (MPS I),  
20 glycogen storage disorder type II (Pompe), and other genetic conditions that have

